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Abstract
Background: Immunization with murine pneumotropic virus virus-like particles carrying Her2/neu (Her2MPtVLPs) prevents
tumour outgrowth in mice when given prophylactically, and therapeutically if combined with the adjuvant CpG. We
investigated which components of the immune system are involved in tumour rejection, and whether long-term
immunological memory can be obtained.
Methodology and Results: During the effector phase in BALB/c mice, only depletion of CD4
+ and CD8
+ in combination,
with or without NK cells, completely abrogated tumour protection. Depletion of single CD4
+,C D 8
+ or NK cell populations
only had minor effects. During the immunization/induction phase, combined depletion of CD4
+ and CD8
+ cells abolished
protection, while depletion of each individual subset had no or negligible effect. When tumour rejection was studied in
knock-out mice with a C57Bl/6 background, protection was lost in CD4
2/2CD8
2/2 and CD4
2/2, but not in CD8
2/2 mice.
In contrast, when normal C57Bl/6 mice were depleted of different cell types, protection was lost irrespective of whether
only CD4
+,o n l yC D 8
+,o rC D 4
+ and CD8
+ cells in combination were eradicated. No anti-Her2/neu antibodies were
detected but a Her2/neu-specific IFNc response was seen. Studies of long-term memory showed that BALB/c mice
could be protected against tumour development when immunized together with CpG as long as ten weeks before
challenge.
Conclusion: Her2MPtVLP immunization is efficient in stimulating several compartments of the immune system, and induces
an efficient immune response including long-term memory. In addition, when depleting mice of isolated cellular
compartments, tumour protection is not as efficiently abolished as when depleting several immune compartments together.
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Introduction
Different forms of immunotherapeutic strategies against cancer
are constantly being investigated as complements to conventional
cancer treatments. The proto-oncogene Her2/neu [1] is an
attractive tumour antigen for immunotherapy against breast cancer
since it is overexpressed in some 20% of all breast cancers and in
addition, the transformed phenotype is dependent on its expression.
Moreover, immune responses to Her2/neu are frequently found in
patients with Her2/neu positive breast cancer, proving that
tolerance to this tumour antigen can be broken in humans [2,3].
Capsid proteins of some viruses can spontaneously self-assemble
into viral capsids known as virus-like particles (VLPs) [4–6], which
can be used as vaccines and vectors for gene and immune therapy.
The best known are the VLP vaccines against human papilloma-
virus (HPV) types 6, 11, 16 and 18 [7]. Additionally, vaccination
with chimeric VLPs (cVLPs) carrying various tumour antigens has
been shown to prevent tumour outgrowth in different mouse
models [8–11].
We have previously used cVLPs based on murine polyomavirus
and murine pneumotropic virus as vaccines against Her2/neu
expressing tumours. These cVLPs carry a fusion protein between
the C-terminal part of the VP2 protein and the extracellular and
transmembrane domains of human Her2/neu (Her2MPyVLPs and
Her2MPtVLPs, respectively). We have shown that a single
prophylactic vaccination with Her2MPyVLPs or Her2MPtVLPs
protected .90% of mice against outgrowth of a tumour cell line
expressing the homologous human Her2/neu protein (D2F2/E2)
[8,11]. In addition, therapeutic immunization with Her2MPtVLPs
together with the adjuvant CpG as late as six days after challenge
resulted in 80% tumour-free mice [11].
The immune response was demonstrated to be Her2/neu-
specific since Her2MPyVLP immunization did not induce
rejection of the parental D2F2 cell line (lacking the transfected
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immunized mice secreted IFNc when incubated together with
D2F2/E2, or CD8
+ Her2/neu immunodominant epitopes, but not
when incubated with D2F2 cells or control peptide epitopes as
shown by ELISPOT [8,11]. However, an antibody response to
Her2/neu was never demonstrated in this system [8,11,12].
Together the findings in vitro indicated that tumour rejection
using Her2MPyVLPs and Her2MPtVLPs was primarily mediated
by CD8
+ cytotoxic T cells, but whether other immune cells were
also involved was never pursued. Further information regarding
these immune mechanisms in vivo, when using Her2/neu-cVLPs,
including studies on long-term memory would be of great value to
further improve the efficacy of vaccination.
In this study we have elucidated which components of the
immune system that are important for tumour protection, both in
the induction and the effector phases, after vaccination with
cVLPs from murine pneumotropic virus. The effects of
Her2MPtVLP vaccination were followed in BALB/c and
C57Bl/6 mice. Depletion of CD4
+, CD8
+ or both CD4
+ and
CD8
+ T cells, as well as NK cells, was performed to find out which
of these cell types are of importance for the obtained immunity. In
parallel, C57Bl/6 knock-out mice lacking CD4
+, CD8
+ or both
CD4
+ and CD8
+ T cells were used. We have also investigated
whether long-term immunological memory can be induced by
Her2MPtVLPs.
Materials and Methods
Ethics statement
CD4
2/2, CD8
2/2 and CD4
2/2CD8
2/2 C57Bl/6 (H-2
b) mice
were with C57Bl/6 and BALB/c (H-2
d), bred and maintained at
MTC Karolinska Institutet and the project conducted according
to Ethical permission N331/08 from Stockholms Norra Djurfor-
soksetiska Namnd, Sweden.
Antibodies and reagents
Anti-CD4 (clone GK1.5) and anti-CD8 (clone TIB105) mono-
clonal antibodies (mAbs) were purchased from Mabtech (Nacka,
Sweden). Anti-asialo GM1 polyclonal antibody was obtained from
Wako Chemicals (Neuss, Germany). Anti-CD4-FITC, anti-CD8-
FITC, anti-CD3-FITC and anti-CD49b-PE (clone DX5) as well as
anti-Her2/neu-PE and its isotype control were obtained from BD
Biosciences Pharmingen (San Diego, CA, USA). CpG 1826 was
obtained from CyberGene (Stockholm, Sweden).
Cell lines
D2F2/E2 cells (H-2
d) expressing the human Her2/neu protein
[13] were cultured as described [12]. EL4 cells (H-2
b) [14] were
transfected with the pcDNA3/HER-2 plasmid (harbouring full-
length human Her2/neu from pVAX/E2A [15] and the neomycin
resistance gene) using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s instructions,
to obtain a Her2/neu positive H-2
b cell line. Cells were cloned and
analysed for surface expression of Her2/neu by flow cytometry using
the anti-Her2/neu-PE antibody. The clone (EL4-Her2) with the
strongest Her2/neu expression was expanded and passaged once in
vivo to improve its quality and then maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% FCS, penicillin/
streptomycin and 800 mg/ml G418 antibiotic solution.
Construction of VLPs
The generation and purification of Her2MPtVLPs and the
control MPtVLPs have been described previously [11,16].
Immunization and tumour cell challenge
Groups of 6–10 female BALB/c or C57Bl/6 mice were given a
single subcutaneous immunization with 50 mg Her2MPtVLPs and
challenged 14 days later subcutaneously in the flank with 5610
4
D2F2/E2 cells or 1–2610
3 EL4-Her2 cells. Tumour size was
measured twice a week and mice carrying a tumour .1m m
3 were
considered as tumour-bearing. Mice were sacrificed when the
largest tumour diameter reached 10 mm. For long-term memory
experiments, groups of 10 female BALB/c mice were immunized
with 50 mg Her2MPtVLPs alone, or together with 50 mg CpG, 10
or 6 weeks before challenge. As a positive control, immunization
with 50 mg Her2MPtVLPs was carried out 14 days prior to
tumour challenge.
In vivo depletion of immune cell subsets during the
immunization or effector phases
For depletion of CD4
+ and CD8
+ cells in the immunization
phase, mice were given intraperitoneal (i.p.) injections of 200 mg
anti-CD4 and/or anti-CD8 mAbs four days and one day before,
and two days after immunization. Depletion was analysed by flow
cytometryfourdaysafteronesingle injectionbystaining splenocytes
with FITC-conjugated anti-CD4 and anti-CD8 antibodies. The
level of depletion was .97% for both T-cell subsets.
For depletion of CD4
+ and/or CD8
+ cells (and in BALB/c also
of NK cells) in the effector phase, mice were injected i.p. with
200 mg anti-CD4 mAb, 200 mg anti-CD8 mAb and/or 20 ml anti-
asialo GM1 antibody. The first depletion was performed two days
before tumour cell challenge, and then every 4–5 days until day 50
after challenge. Depletion of both T-cell subsets was .97% when
tested four days after one single injection and 70–80% at the day
of termination of the experiment. NK cells decreased from 8–10%
of splenocytes to 2–3% as analysed by flow cytometry using anti-
CD49b (clone DX5) and anti-CD3 mAbs (NK cells being
CD49b
+CD3
2). This level of depletion is in line with other
reports [17–20].
ELISPOT assay and measurement of Her2/neu antibodies
ELISPOT as well as measurement of Her2/neu antibodies were
performed as described previously [11].
Statistical analyses
Student’s t-test was used to analyse differences in ELISPOT
data. Differences in tumour takes were analysed using Fisher’s
exact two-tailed test or, when indicated, the Peto-Peto-Wilcoxon
test.
Results
Depletion of both CD4
+ and CD8
+ T cells is necessary to
abolish the induction of an immune response in BALB/c
mice
BALB/c mice were depleted of CD4
+ and/or CD8
+ cells in the
induction phase using i.p. injections of mAbs days 24, 21 and +2
in relation to Her2MPtVLP immunization. Mice were inoculated
with 5610
4 D2F2/E2 tumour cells 14 days after immunization
and followed for tumour outgrowth (Figure 1). Her2MPtVLP
immunized non-depleted mice stayed tumour-free throughout the
69-day observation period, while all unimmunized control mice
developed tumours within 13 days. A considerable immunization
effect was still observed after CD4
+ or CD8
+ depletion, since 80%
and 90% of the mice respectively stayed tumour-free during the
whole observation period (p,0.001 compared to unimmunized
mice in both cases). However, the protective effect was abolished
VLPs as Vaccines
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+ and CD8
+ cells were depleted, and all mice
developed tumours in a timeframe similar to that in unimmunized
animals.
The in vivo data above were complemented with the monitoring
of IFNc responses by ELISPOT. Mice were depleted of CD4
+
and/or CD8
+ cells 5 days and 2 days before immunization, and
thereafter immunized with Her2MPtVLPs. ELISPOT analyses
were performed 7 days later. Depletion of CD4
+ cells did not affect
the induced IFNc response as compared to non-depleted mice
(p=0.68) (Figure 2). As expected, depletion of CD8
+ cells, or
depletion of CD4
+ in combination with CD8
+ cells, almost
completely abolished the IFNc response (p,0.01 in both cases)
(Figure 2).
Depletion of both CD4
+ and CD8
+ T cells in the effector
phase is necessary to abolish tumour rejection after
Her2MPtVLP vaccination in BALB/c mice
BALB/c mice were immunized with Her2MPtVLPs and
challenged with 5610
4 D2F2/E2 tumour cells 14 days later.
CD4
+ cells, CD8
+ cells or NK cells were depleted separately or
together by i.p. injections of monoclonal antibodies (for CD4
+
and CD8
+ cells), or anti-asialo GM1 antibodies (for NK cells),
every 4–5 days starting two days before challenge. The
experiment was performed twice with similar results, and the
results are summarised in Table 1. Non-depleted Her2MPtVLP
immunized mice remained tumour-free, while all but one
unimmunized control mouse developed tumours. Depletion of
CD4
+ and CD8
+ cells in combination, with or without depletion
of NK cells, almost completely abolished the anti-tumour effect.
Single depletion of CD4
+,C D 8
+ or NK cells still resulted in a
statistically significant anti-tumour response compared to unim-
munized mice. However, depletion of either CD4
+ cells or NK
cells resulted in reduced protection compared to non-depleted
immunized mice (Table 1).
Tumour rejection by Her2MPtVLPs is induced in CD8
2/2
single, but not in CD4
2/2 single or CD4
2/2CD8
2/2
double knock-out C57Bl/6 mice
As a complement to the depletion of different subsets of immune
cells in normal BALB/c mice, tumour rejection experiments were
also performed in CD4
2/2 single, CD8
2/2 single, or CD4
2/2
CD8
2/2 double knock-out C57Bl/6 mice. EL4-Her2, derived
from EL4 cells (H-2
b) transfected with a plasmid expressing human
Her2/neu, were used for tumour challenge. Surface expression of
Her2/neu was re-confirmed by flow cytometry prior to tumour
challenge (Figures 3a and b). To ensure a positive immune
response, normal C57Bl/6 mice, in parallel to C57Bl/6 knock-out
mice, were immunized subcutaneously with Her2MPtVLPs and
challenged with EL4-Her2 cells two weeks later. The results from
two independent experiments are summarized in Table 1.
Her2MPtVLP immunized normal and CD8
2/2 single knock-out
C57Bl/6 mice were protected against tumour outgrowth (p,0.05
and p,0.01, respectively), indicating that these groups of mice
could mount an immune response after Her2MPtVLP immuni-
zation, while most unimmunized mice developed tumours
Figure 1. Tumour rejection following depletion of immune cells in the induction phase in BALB/c mice. Mice immunized with
Her2MPtVLPs were depleted of CD4
+ cells (N), CD8
+ cells (*), or both cell types (O), 4 days and 1 day before immunization, and 2 days after
immunization, respectively. Unimmunized mice (x) and non-depleted Her2MPtVLP immunized mice (D) were included as negative and positive
controls respectively. Mice were challenged with 5610
4 D2F2/E2 cells 2 weeks after immunization.
doi:10.1371/journal.pone.0011580.g001
Figure 2. IFNc responses following depletion of immune cells
in BALB/c mice. Mice were depleted of CD4
+ and/or CD8
+ cells 5 and
2 days before immunisation with Her2MPtVLPs. The IFNc response was
measured 7 days later by stimulating splenocytes with the immuno-
dominant CD8
+ peptide Her263–71 or the control peptide NP118–126.
Average values of triplicates from six animals are shown. Background
values (stimulation in the absence of peptide) have been subtracted.
Error bars represent S.E.
doi:10.1371/journal.pone.0011580.g002
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2/2 single and CD4
2/2CD8
2/2 double knock-
out C57Bl/6 mice, there was no significant difference in tumour
takes between Her2MPtVLP immunized and unimmunized mice
(Table 1).
Depletion of either CD4
+ or CD8
+ cells in the effector
phase completely abrogates tumour rejection in C57Bl/6
mice
Since the results from the depletion of immune cells in BALB/
c mice were not completely in agreement with the results from
the C57Bl/6 knock-out mice, we performed a depletion
experiment in C57Bl/6 mice. C57Bl/6 mice were immunized
with Her2MPtVLPs (50 mg) and challenged with 2610
3 EL4-
Her2 cells 14 days later. CD4
+ and CD8
+ cells were depleted
separately or together using i.p. injections of anti-CD4 and anti-
CD8 mAbs starting two days before tumour cell challenge, and
thereafter every 4–5 days. EL4-Her2 tumour outgrowth in the
different groups is shown in Table 1. In this system, where the
degree of immunity was less pronounced, depletion of CD4
+ cells
or CD8
+ cells, or CD4
+ and CD8
+ cells in combination,
abolished the Her2MPtVLP immunization effect completely
(Table 1). However, only depletion of CD4
+ cells resulted in a
statistically significant difference compared to non-depleted
Her2MPtVLP immunized mice (p,0.05, Peto-Peto-Wilcoxon
test).
Her2MPtVLP immunization induces long-term T cell
memory responses
As demonstrated above and reported previously [8,11,12],
inhibition of tumour outgrowth is regularly 95–100% when BALB/c
mice are immunized with Her2/neu-cVLPs two weeks prior to
challenge. Due to this successful anti-tumour response, we examined
whether long-term immunological memory could be obtained. For
this purpose, BALB/c mice were immunized with Her2MPtVLPs
with or without CpG either six or ten weeks before challenge. Two
experiments were performed and the results from the first experiment
are shown in Figure 4 and the results from both experiments are
summarised in Table 2. All but one unimmunized mouse developed
tumours. Combining Her2MPtVLPs with CpG immunization six
weeks before challenge resulted in the same level of protection as
immunization two weeks prior to challenge (p,0.001 compared to
unimmunized mice). Immunization with Her2MPtVLPs and CpG as
long as ten weeks before challenge still resulted in significant
protection compared to unimmunized mice (60% protection,
p,0.01) (Table 2). Finally, when tumour cells were given six weeks
after immunization with Her2MPtVLPs without CpG, protection
was 80% (p,0.001) (Table 2). In accordance with these results, an
IFNc response specific for the immunodominant CD8
+ peptide
Her263–71 could be demonstrated by ELISPOT up to ten weeks after
immunization with Her2MPtVLPs and CpG. However, the response
was weak at both six and ten weeks (Figure 5).
Table 1. Tumour takes after depletion of CD4
+ cells, CD8
+ cells and/or NK cells in the effector phase in BALB/c and C57Bl/6 mice,
respectively, as well as tumour takes in C57Bl/6 knock-out mice.
Mouse strain Immunogen Cells depleted Takes Total takes (%) p-valuesa p-valuesb
Exp.
c 1 Exp. 2
BALB/c Her2MPtVLPs - 0/10 0/10 0/20 (0) ,0.001
Her2MPtVLPs CD4
+ 3/10 3/9 6/19 (32) ,0.001 ,0.01
Her2MPtVLPs CD8
+ 2/10 0/10 2/20 (10) ,0.001 ns
d
Her2MPtVLPs CD4
+/CD8
+ 8/10 7/10 15/20 (75) ns ,0.001
Her2MPtVLPs CD4
+/CD8
+/NK 9/10 6/10 15/20 (75) ns ,0.001
Her2MPtVLPs NK 4/10 8/10 12/20 (60) ,0.05 ,0.001
-- 10/10 9/10 19/20 (95) ,0.001
B6
e wild-type - - 5/7 8/10 13/17 (76)
Her2MPtVLPs - 2/7 3/10 5/17 (29) ,0.05
B6 CD4
+ KO
f -- 4/7 5/6 9/13 (69)
Her2MPtVLPs - 4/7 4/6 8/13 (62) ns
B6 CD8
+ KO - - 5/7 7/10 12/17 (71)
Her2MPtVLPs - 0/7 3/10 3/17 (18) ,0.01
B6 CD4
+/CD8
+ KO - - 6/7 9/9 15/16 (94)
Her2MPtVLPs - 6/7 8/9 14/16 (88) ns
B6 wild-type Her2MPtVLPs CD4
+ 6/7 6/7 (86) ns ,0.05
Her2MPtVLPs CD8
+ 5/7 5/7 (71) ns ns
Her2MPtVLPs CD4
+/CD8
+ 5/7 5/7 (71) ns ns
Mice were immunized with Her2MPtVLPs and 2 weeks later challenged with 5610
4 D2F2/E2 cells (BALB/c) or 1–2610
3 EL4-Her2 cells (C57Bl/6). P-values were calculated
using Fisher’s exact two-tailed test for BALB/c mice depleted of different cells as well as for C57Bl/6 knock-out mice while Peto-Peto-Wilcoxon was used for C57Bl/6 mice
depleted of various cell types.
acompared to unimmunized mice.
bcompared to non-depleted immunized mice.
cexperiment.
dnot significant.
eC57Bl/6 mice.
fknock-out.
doi:10.1371/journal.pone.0011580.t001
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In this study, the role of CD8
+, CD4
+ and NK cells in tumour
rejection was examined after Her2MPtVLP immunization.
Previous reports strongly indicated that CD8
+ T cells play a role,
but the effect of other cell types was never followed [8,11]. In
addition, different ways to obtain long-term memory were
explored.
In BALB/c mice immunized with Her2MPtVLP, depletion of
both, but not only either CD4
+ or CD8
+ cells was required to
eliminate inhibition of tumour growth, irrespective of whether the
anti-CD4 and/or anti-CD8 mAbs were delivered before immu-
nization, or before tumour challenge. Depletion of NK cells was
only performed in the effector phase and did not add any effect to
anti-CD4 and anti-CD8 antibody treatments, but did impair
immunity when depleted alone. Tumour rejection experiments
were also done in Her2MPtVLP immunized normal and CD4
2/2
and CD8
2/2 single, as well as CD4
2/2CD8
2/2 double knock-
out C57Bl/6 mice. Similar to BALB/c mice, protection against
tumour outgrowth was obtained in both normal and CD8
2/2
mice, but not in CD4
2/2CD8
2/2 mice. However, in contrast to
BALB/c mice, protection was lost in CD4
2/2 mice, and after
depletion of either CD4
+ and/or CD8
+ cells in normal C57Bl/6
mice.
The fact that tumour rejection was obtained after depletion of
CD8
+ cells in BALB/c mice was unexpected in comparison to our
previous results [8,11]. This could have been due to an antibody
response. However, anti-Her2/neu antibodies have never been
found using these vaccines [8,11,12]. In addition, the mice were
still protected after CD4
+ cell depletion at the time of
immunization, suggesting that if antibodies were raised, this
occurred independent of CD4
+ cells. Moreover, tumour protection
was lost after combined depletion of CD4
+ and CD8
+ cells, which
should not have had a more profound effect on antibody titres
than depletion of CD4
+ cells alone. It is also unlikely that tumour
inhibition after depletion was due to low numbers of remaining
CD4
+ or CD8
+ specific T-cells, since depletion was .97% initially
for both subsets, and 70–80% three weeks after the last mAb
injection. Instead, it is possible that cytotoxic CD4
+ T cells play a
role in this vaccination model. This is also supported by the
experiments performed in the, CD4
2/2, CD8
2/2 and CD4
2/2
CD8
2/2 C57Bl/6 mice, discussed in more detail below.
Notably, CD4
+ and CD8
+ cell subsets could be depleted before
immunization or tumour challenge in BALB/c mice, without any
significant effect on inhibition of tumour growth, while the
combined depletion in the induction phase abrogated tumour
protection. The effect of the latter on the induction phase could
however not be isolated from that on the effector phase, due to the
prolonged depletion of these populations as mentioned above.
Figure 3. Surface expression of Her2/neu on EL4-Her2 cells.
Surface expression of human Her2/neu on EL4 (A), and EL4-Her2 cells
(B), analysed by flow cytometry using the anti-Her2/neu-PE antibody
(solid line) or relevant isotype control (dashed line).
doi:10.1371/journal.pone.0011580.g003
Figure 4. Induction of long-term tumour rejection responses. BALB/c mice were immunized with Her2MPtVLPs alone (*) or Her2MPtVLPs in
combination with CpG (D) and challenged 6 weeks later with 5610
4 D2F2/E2 cells. Unimmunized mice (x) and mice immunized with MPtVLPs and
CpG (N) were included as negative controls, while mice immunized with Her2MPtVLPs 2 weeks prior to challenge were used as positive controls (%).
doi:10.1371/journal.pone.0011580.g004
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GM1 antibodies indicates that NK cells play a role. Asialo-GM1 is
expressed on NK cells and on about 3% of CD8
+ cells in BALB/c
mice [21], while expression on CD4
+ cells in this mouse strain has
to our knowledge not been studied. Interestingly, after infection of
mice with viruses such as respiratory syncytial virus and
lymphocytic choriomeningitis virus, the expression of asialo-
GM1 increases on both CD4
+ and CD8
+ cells. More than 90%
of virus-specific CD4
+ as well as CD8
+ T cells can be asialo-GM1
positive [22,23]. Whether upregulation of asialo-GM1 also occurs
after inoculation with murine pneumotropic virus or MPtVLPs has
not been examined, but it is possible that injection of anti-asialo
GM1 antibodies in this study could also have had an effect on
CD4
+ and CD8
+ cells. This hypothesis is possibly supported by the
fact that the combined depletion effect on CD4
+ and CD8
+ cells
was not enhanced by NK cell depletion.
Normal and CD4
2/2, CD8
2/2 single and double knock-out
C57Bl/6 mice were also included in rejection studies. However,
these systems were not as stringent since it was more difficult with
C57Bl/6 EL4-Her2 both to obtain tumour outgrowth in control
mice, and to achieve tumour protection in immunized mice.
Depletion or knockout of both CD4
2/2 and CD8
2/2 cells
abrogated protection against tumour outgrowth, in accordance to
that discussed above in BALB/c mice. Similarly, CD8
2/2 mice
were protected. However, the immunization effect was lost in
CD4
2/2 mice, and since anti-Her2/neu antibodies were not
shown here or previously [8,11,12], the results again suggest that
CD4
+ cytotoxic T cells could be active. When manipulating the
system by depletion of CD4
+ and/or CD8
+ cells, it was easier to
obtain an abrogation of the anti-tumour response compared to the
BALB/c model. However, depletion of CD4
+ cells, seemed again
to result in a more profound effect.
Our present interpretation is that there is a redundancy of
immune effectors after the very efficient Her2MPtVLP vaccination
in BALB/c mice, and that when a single component is abolished a
reasonable immune response is still obtained. In a more vulnerable
system, i.e. in C57Bl/6 normal and knock-out mice abrogation of
one cell type makes the mice sensitive to tumour outgrowth. Hence,
Her2MPtVLP vaccination has the ability to activate several types of
immune cells, and it is therefore necessary to deplete several
immune components to abrogate the immune response completely.
To the very best of our knowledge, only one other study has in
detail investigated the immune compartments in vivo responsible
for tumor rejection following vaccination with cVLPs. Greenstone
et al showed that cVLPs based on HPV16 induced protection
against tumor outgrowth in normal and MHC class II-deficient
mice as well as mice depleted of NK cells [10]. However, mice
lacking b2-microglobulin or perforin were not protected implying
that tumour protection was mediated by MHC class-I restricted
cytotoxic T cells independent of CD4
+ T cells [10]. Whether the
same is true for cVLPs from murine polyomavirus and murine
pneumotropic virus has never been studied. Although papilloma-
viruses and polyomaviruses are structurally similar, their VLPs
differ. For instance, HPV VLPs induce maturation of dendritic
cells [24] while most polyomavirus VLPs do not [11,12,24,25] and
they also bind to different cell surface receptors [26–29].
Othertumourvaccineshavebeen studied moreextensivelyinthis
context. Tumour protection after vaccination with vaccines based
on DNA, dendritic cells or adenoviruses, is often lost following
depletion of CD8
+ cells during the effector phase [15,30–37]. On
the contrary, there are other studies with DNA vaccines, where
eliminationofCD4
+cellsabolishestumourprotectionintheeffector
phase [15,31,38,39]. Depletion of NK cells has also been shown to
abrogate protection in some DNA vaccination models [30,38,40].
However, dependenceon NKcellsis not ascommonasdependence
on CD4
+ and CD8
+ cells.
Also with regard to studies on tumor vaccines in knock-out mice
the results vary. In some studies with DNA vaccines in knock-out
mice, the simultaneous presence of CD4
+ and CD8
+ cells is
necessary [40–42]. However, one study with a vaccine based on
vaccinia virus showed requirement for CD4
+ cells [43], while
another with an adenovirus-based vaccine showed dependence on
CD8
+ cells [44]. Another relevant study by Wen et al showed that
immunity in mice against a methylcholanthrene induced fibrosar-
coma was induced in both CD4
2/2 and CD8
2/2 single knock-out
mice, but not in CD4
2/2CD8
2/2 double knock-out mice [45],
which is then in line with our results in BALB/c mice. Hence, the
results differ markedly between various studies and seem to
depend both on the tumour antigen, the kind of vaccine and the
animal model. It is therefore not obvious beforehand which
Table 2. Tumour takes after immunization of BALB/c mice 6
and 10 weeks before challenge with 56104 D2F2/E2 cells.
Immunogen Takes Total takes (%) p-values
a
Exp.
b 1E x p . 2
Her2MPtVLPs+CpG,
210 weeks
nd
c 4/10 4/10 (40) ,0.01
Her2MPtVLPs+CpG,
26 weeks
0/10 1/10 1/20 (5) ,0.001
Her2MPtVLPs,
26 weeks
2/10 nd 2/10 (20) ,0.001
Her2MPtVLPs+CpG,
22 weeks
0/10 1/10 1/20 (5) ,0.001
MPtVLPs+CpG,
22 weeks
10/10 nd 10/10 (100) ns
d
Unimmunized 10/10 9/10 19/20 (95) ref
ap-values calculated using Fisher’s exact two-tailed test, compared to
unimmunized mice.
bexperiment.
cnot done.
dnot significant.
doi:10.1371/journal.pone.0011580.t002
Figure 5. Long-term IFNc responses after Her2MPtVLP immu-
nization. BALB/c mice were immunized with Her2MPtVLPs with CpG
either 10 weeks (a), 6 weeks (b) or 1 week (d) before ELISPOT analysis, or
with Her2MPtVLPs without CpG 6 weeks (c) or 1 week (e) before
ELISPOT. Unimmunized mice were included as negative controls (f).
Splenocytes were stimulated with the immunodominant CD8
+ peptide
Her263–71 or the control peptide NP118–126. Average values of triplicates
from 4 animals are shown. Background values (stimulation in the
absence of peptide) have been subtracted. Error bars represent S.E.
doi:10.1371/journal.pone.0011580.g005
VLPs as Vaccines
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particular model, and every single model should be studied
individually.
To investigate whether Her2MPtVLPs can induce long-term
memory, immunization either with or without CpG was
performed up to ten weeks before challenge. A statistically
significant protection was obtained when Her2MPtVLPs com-
bined with CpG were given as long as ten weeks prior to challenge.
Although we have not confirmed that the T cells responsible for
protection have a memory phenotype [46,47], it is known that an
immune response so long after immunization is normally mediated
by memory T cells [46,48,49].
In conclusion, immunization with Her2MPtVLPs is efficient in
stimulating several compartments of the immune system, and
induces an efficient immune response including a memory T cell
response. Hence, when depleting mice of isolated compartments,
tumour protection is not as efficiently abolished as when depleting
several immune compartments together.
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